Ctx Platforms ^{For Profit}

Ctx Platforms is a biotech company developing a targeted protein delivery system for diagnosing and treating cancer. CTX-Platforms is launching a cancer-targeting peptide platform based on a patent-pending synthetic molecule derived from scorpion venom, which can easily penetrate the blood-brain barrier as well as solid tumors outside the central nervous system. The company is developing specific proteins to serve as bio carriers. These proteins are derived from various scorpion venoms, expressing unique characteristics, namely, selective affinity to cancer tissues, high stability, and effective penetrability to the blood-brain barrier (BBB). It holds intellectual property for a synthetic peptide based on a natural molecule from scorpion venom. The peptide has selective affinity to cancer cells, it penetrates the BBB and enables its use in therapy and diagnostics.